北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus
作者: Zhang, Xiaodong; Shen, Lin; Li, Jie; Li, Yan; Li, Jian; Jin, Maolin
关键词: squamous-cell carcinoma of the esophagus ; paclitaxel ; cisplatin ; chemotherapy
刊名: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
发表日期: 2008-02-01
DOI: 10.1097/COC.0b013e3181131ca9
卷: 31, 期:1, 页:29-33
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: FOLINIC ACID ; CANCER ; 5-FLUOROURACIL ; THERAPY ; TAXOL ; ADENOCARCINOMA ; FLUOROURACIL ; ETOPOSIDE
英文摘要:

Objective: To evaluate the response rate, survival, and toxicities of paclitaxel plus cisplatin combination in patients with advanced or metastatic squamous-cell carcinoma of the esophagus.

Methods: Thirty-nine patients with definite measurable indices and no prior chemotherapy were enrolled. Patients were treated with paclitaxel 175 mg/m(2) and cisplatin 75 mg/m(2) by 2-hour infusion on day 1. Treatment was repeated every 21 days.

Results: Thirty-nine patients were enrolled of which 35 patients were eligible to be evaluated to have had a response. The overall response rate was 48.6% [95% confidence interval (CI), 0.31-0.65 with complete and partial response rates of 2.8% and 45.7%, respectively. The median time to progression was 7 months, and median survival time of all patients was 13 months. There was a significant difference in the median overall survival between the patients who had showed response versus those who had not (P = 0.006). Median survival was 17 (95% Cl, 11.9-22.0) and 10 months (95% Cl, 7.6-12.4), respectively. The 1-year survival probability was 39%. Relief of dysphagia and pain were observed in 86.2% of all the patients. The most common toxicities were neutropenia and alopecia. No grade 4 toxicities and treatment-related deaths were recorded in all patients.

Conclusion: Paclitaxel and cisplatin is a promising treatment for patients with squamous-cell carcinoma of the esophagus. The toxicity of this regimen is within acceptable range.

语种: 英语
WOS记录号: WOS:000253102700005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/61180
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Beijing Canc Hosp, Sch Oncol, Beijing Inst Canc Res,Dept Gastrointestinal Med, Beijing, Peoples R China

Recommended Citation:
Zhang, Xiaodong,Shen, Lin,Li, Jie,et al. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS,2008,31(1):29-33.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhang, Xiaodong]'s Articles
[Shen, Lin]'s Articles
[Li, Jie]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhang, Xiaodong]‘s Articles
[Shen, Lin]‘s Articles
[Li, Jie]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace